TFFP - COVID-19 Update: Vaccines Treatments And Lockdowns Investment Implications

• UK government scoops the US in authorizing the use of the Pfizer/BioNTech vaccine; roll out to commence next week. FDA and EU approval probably not far off.
• The Pfizer/BioNTech vaccine has first mover advantage. BioNTech stock could experience further gains at least in the short term. Moderna is likely to get a boost too.
• Treatments seem to be going backwards with doubts about remdesivir and lacklustre monoclonal antibody treatments for early stage disease from Regeneron and Eli Lilly.
• With Europe and the US confronting new outbreaks, expect a tough winter and the need for restrictions and lockdowns, which might mean market setback unless substantial additional government support is given.

For further details see: